DOCSLIB.ORG

有限公司 API Antineoplastic Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
有限公司 API Antineoplastic Agents ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com API Antineoplastic Agents Product Highlight The following is a selection of products we have sourced and supplied to our customers globally. For detailed specifications, certificates of analysis, supply position, and tailored pricing, please contact us at [email protected] . For any unlisted products that you require, feel free to contact us for support. We can source or custom manufacture at your specification. Product Code CAS Product Name PH-3107DA 522-17-8 (-)-DEGUELIN PH-4360CF 989-51-5 (-)-EPIGALLOCATECHIN GALLATE MIS-6071 32981-86-5 10-DEACETYLBACCATIN III (REFERENCE GRADE) MIS-5741 78432-77-6 10-DEACETYLPACLITAXEL (REFERENCE GRADE) PH-0441BA 19685-09-7 10-HYDROXYCAMPTOTHECIN 64439-81-2 (UNSPECIFIED ISOMER) PH-0441BC 19685-09-7 10-HYDROXYCAMPTOTHECIN (REFERENCE GRADE) 64439-81-2 (UNSPECIFIED ISOMER) PH-3394A 533-67-5 2-DEOXY-D-RIBOSE PH-1956DA 951-78-0 2'-DEOXYURIDINE PH-0865F 38390-45-3 3',4'-ANHYDROVINBLASTINE MIS-10676 75567-37-2 3-INGENYL ANGELATE (REFERENCE GRADE) 849146-39-0 Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 57 Product Code CAS Product Name PH-1578EK 2498-50-2 4-AMINOBENZAMIDINE DIHYDROCHLORIDE PH-1541D 23363-35-1 4'-DEMETHYLEPIPODOPHYLLOTOXIN-9 BETA-GLUCOPYRANOSIDE PH-4586B 1716-12-7 4-PHENYLBUTYRIC ACID SODIUM SALT MIS-4544 1009820-21-6 5-[(3-CHLOROPHENYL)AMINO]BENZO[C]-2,6-NAPHTHYRIDINE-8-CARBOXYLIC ACID PH-0751A 320-67-2 5-AZACYTIDINE PH-1956KA 59-14-3 5-BROMO-2'-DEOXYURIDINE PH-0404 51-21-8 5-FLUOROURACIL PH-0451AA 58-05-9 5-FORMYL-5,6,7,8-TETRAHYDROFOLATE PH-0451CA 134-35-0 5-METHYLTETRAHYDROFOLATE PH-0451CC 68792-52-9 5-METHYLTETRAHYDROFOLIC ACID DISODIUM SALT PH-0418A 50-44-2 6-MERCAPTOPURINE (ANHYDROUS) PH-0418D 4988-64-1 6-MERCAPTOPURINE RIBOSIDE PH-0441CA 86639-52-3 7-ETHYL-10-HYDROXYCAMPTOTHECIN PH-0441FA 78287-27-1 7-ETHYLCAMPTOTHECIN PH-1825FB 5300-03-8 9-CIS-RETINOIC ACID PH-2045BA 71751-41-2 ABAMECTIN MIS-29640 1231929-97-7 ABEMACICLIB MIS-3754 154229-19-3 ABIRATERONE MIS-7593 154229-18-2 ABIRATERONE ACETATE PH-1743A 57576-44-0 ACLARUBICIN MIS-3395 61276-17-3 ACTEOSIDE (REFERENCE GRADE) 22323-52-0 PH-3456 50-76-0 ACTINOMYCIN D PH-1698CA 60-92-4 ADENOSINE-3',5'-CYCLIC MONOPHOSPHATE ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 2 of 57 Product Code CAS Product Name MIS-11622 850140-72-6 AFATINIB PH-2237DA 483-04-5 AJMALICINE MIS-11629 1256580-46-7 ALECTINIB PH-1825F 302-79-4 ALL-TRANS-RETINOIC ACID PH-3676NA 481-72-1 ALOE-EMODIN PH-3676NC 481-72-1 ALOE-EMODIN (REFERENCE GRADE) MIS-0818 1617-53-4 AMENTOFLAVONE MIS-5317 1617-53-4 AMENTOFLAVONE (REFERENCE GRADE) PH-4576A 20537-88-6 AMIFOSTINE PH-2305 125-84-8 AMINOGLUTETHIMIDE PH-2733 54-62-6 AMINOPTERIN PH-5307 51264-14-3 AMSACRINE PH-4538FA 29883-15-6 AMYGDALIN PH-1577AA 120511-73-1 ANASTROZOLE PH-0416B 10212-25-6 ANCITABINE HYDROCHLORIDE MIS-5591 5508-58-7 ANDROGRAPHOLIDE (REFERENCE GRADE) PH-1422AA 66584-72-3 ANSAMITOCIN P-3 PH-1422AB 66547-09-9 ANSAMITOCIN P-3' PH-1281AA 170729-80-3 APREPITANT PH-2240 472-61-7 ASTAXANTHIN 7542-45-2 PH-2083A 64228-81-5 ATRACURIUM BESILATE PH-1404EG 319460-85-0 AXITINIB PH-3625A 123040-69-7 ((+/-)-ISOMER) AZASETRON 123039-99-6 ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 3 of 57 Product Code CAS Product Name PH-0418C 446-86-6 AZATHIOPRINE PH-1404KA 887650-05-7 BAFETINIB 859212-16-1 (4,5'-BIPYRIMIDINE ISOMER) PH-5213A 16506-27-7 BENDAMUSTINE PH-5213B 3543-75-7 BENDAMUSTINE HYDROCHLORIDE 97832-05-8 (UNSPECIFIED HYDROCHLORIDE) PH-0009A 499-44-5 BETA-THUJAPLICIN PH-5689 473-98-3 BETULIN PH-5199 472-15-1 BETULINIC ACID MIS-5617 472-15-1 BETULINIC ACID (REFERENCE GRADE) PH-0895CA 216974-75-3 BEVACIZUMAB PH-4578AA 90357-06-5 BICALUTAMIDE PH-2570 12758-40-6 BIS(2-CARBOXYETHYLGERMANIUM(IV) SESQUIOXIDE) PH-4107 BLACK COHOSH EXTRACT PH-1460B 11116-32-8 BLEOMYCIN A5 PH-1460BB 55658-47-4 BLEOMYCIN A5 HYDROCHLORIDE PH-1460F BLEOMYCIN A6 PH-1460G 9060-10-0 BLEOMYCIN B2 PH-1460GB BLEOMYCIN B2 TRIHYDROCHLORIDE PH-1460D 67763-87-5 BLEOMYCIN HYDROCHLORIDE PH-1460E 9041-93-4 BLEOMYCIN SULFATE PH-0120 179324-69-7 BORTEZOMIB PH-1404MJ 380843-75-4 BOSUTINIB ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 4 of 57 Product Code CAS Product Name MIS-8616 944396-07-0 BUPARLISIB PH-0397 55-98-1 BUSULPHAN MIS-0535 183133-96-2 CABAZITAXEL PH-1179A 81409-90-7 CABERGOLINE 85329-89-1 (DIPHOSPHATE) PH-1404NE 849217-68-1 CABOZANTINIB PH-0591H 104594-70-9 CAFFEIC ACID PHENETHYL ESTER (CAPE) PH-0591B 58-08-2 CAFFEINE ANHYDROUS PH-1188AA 112965-21-6 CALCIPOTRIENE 112828-00-9 PH-1188AC 147657-22-5 CALCIPOTRIENE MONOHYDRATE PH-0451CE 26560-38-3 CALCIUM 5-METHYLTETRAHYDROFOLATE PH-0451AC 1492-18-8 CALCIUM FOLINATE PH-0451AM 80433-71-2 CALCIUM LEVOFOLINATE PH-0451CM 151533-22-1 CALCIUM LEVOMEFOLATE PH-4360DA 84650-60-2 CAMELIA SINENSIS EXTRACT PH-0417AK 59721-29-8 CAMOSTAT MESILATE PH-0441AA 7689-03-4 CAMPTOTHECIN PH-1404VL 267243-28-7 CANERTINIB 289499-45-2 (DIHYDROCHLORIDE) PH-4874AA 154361-50-9 CAPECITABINE PH-2566K 404-86-4 CAPSAICIN (NATURAL) MIS-5944 404-86-4 CAPSAICIN (REFERENCE GRADE) PH-1490BA 41575-94-4 CARBOPLATIN MIS-5116 868540-17-4 CARFILZOMIB ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 5 of 57 Product Code CAS Product Name PH-2907 61422-45-5 CARMOFUR PH-0388 154-93-8 CARMUSTINE PH-1063F 3650-09-7 CARNOSIC ACID PH-5919A 50935-04-1 CARUBICIN 39472-31-6 PH-0865D 2468-21-5 CATHARANTHINE MIS-6067 24316-19-6 CEPHALOTAXINE (REFERENCE GRADE) PH-0895EA 205923-56-4 CETUXIMAB PH-3362B 94-41-7 CHALCONE 614-47-1 ((E)-ISOMER) PH-0217B 34316-15-9 CHELERYTHRINE PH-0217A 3895-92-9 CHELERYTHRINE CHLORIDE PH-0378 305-03-3 CHLORAMBUCIL PH-5488GA 113852-37-2 CIDOFOVIR 149394-66-1 (DIHYDRATE) 120362-37-0 (SODIUM SALT) PH-1488A 51481-61-9 CIMETIDINE (TYPE A) PH-1488B 51481-61-9 CIMETIDINE (TYPE AB) PH-1490AA 15663-27-1 CISPLATIN PH-5188 4291-63-8 CLADRIBINE PH-0351 130-26-7 CLIOQUINOL PH-5750 123318-82-1 CLOFARABINE PH-1062AA 50-41-9 CLOMIPHENE CITRATE 43054-45-1 (1:X) 911-45-5 (BASE) ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 6 of 57 Product Code CAS Product Name PH-1500AA 303-98-0 COENZYME Q10 PH-2261A 64-86-8 COLCHICINE MIS-6005 64-86-8 COLCHICINE (REFERENCE GRADE) PH-3602AE 71794-92-8 CONJUGATED LINOLEIC ACID (CLA) 26764-25-0 121250-47-3 PH-3214GA CORIOLUS VERSICOLOR BETA-1,3/1,6-D-GLUCAN PH-1404RA 670220-88-9 CRENOLANIB PH-4112FA 42553-65-1 CROCIN I PH-4112FB 42553-65-1 CROCIN I (REFERENCE GRADE) PH-1904A 60137-06-6 CUCURBITACINS PH-4537 66-81-9 CYCLOHEXIMIDE PH-0731 4449-51-8 CYCLOPAMINE (REFERENCE GRADE) PH-0365A 50-18-0 CYCLOPHOSPHAMIDE PH-0365B 6055-19-2 CYCLOPHOSPHAMIDE MONOHYDRATE PH-1926AA 59865-13-3 CYCLOSPORIN A 79217-60-0 PH-1926E 63775-95-1 CYCLOSPORIN B PH-1926B 59787-61-0 CYCLOSPORIN C PH-1926C 63775-96-2 CYCLOSPORIN D PH-1926D 83602-39-5 CYCLOSPORIN H PH-1038FA 427-51-0 CYPROTERONE ACETATE PH-0411A 147-94-4 CYTARABINE PH-0431 4342-03-4 DACARBAZINE PH-1235 827318-97-8 DANUSERTIB ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 7 of 57 Product Code CAS Product Name PH-1267AE 129938-20-1 DAPOXETINE HYDROCHLORIDE PH-1404JA 302962-49-8 DASATINIB 863127-77-9 (MONOHYDRATE) PH-1511B 20830-81-3 DAUNOMYCIN PH-1511 23541-50-6 DAUNORUBICIN HYDROCHLORIDE PH-1985 2353-33-5 DECITABINE PH-3436 5928-25-6 DECURSIN PH-2261F 477-30-5 DEMECOLCINE PH-5028 54024-22-5 DESOGESTREL PH-0941A 50-02-2 DEXAMETHASONE PH-4677 24584-09-6 DEXRAZOXANE PH-3779 69655-05-6 DIDANOSINE PH-1116K 65928-58-7 DIENOGEST PH-1887AB 16208-51-8 DIMESNA PH-1944AE 302-72-7 DL-ALANINE PH-2004BE 114977-28-5 DOCETAXEL MIS-5811 114977-28-5 DOCETAXEL (REFERENCE GRADE) PH-2004BB 148408-66-6 DOCETAXEL TRIHYDRATE PH-1956J 3094-09-5 DOXIFLURIDINE PH-1898B 23214-92-8 DOXORUBICIN PH-1898A 25316-40-9 DOXORUBICIN HYDROCHLORIDE PH-3664A 50-69-1 D-RIBOSE PH-0612 608-66-2 DULCITOL PH-4114 90028-20-9 ECHINACEA EXTRACT ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 8 of 57 Product Code CAS Product Name PH-3142A 70052-12-9 EFLORNITHINE 67037-37-0 ((+/-)-ISOMER) 103957-16-0 ((+)-ISOMER) 66640-93-5 ((-)-ISOMER) PH-3142B 68278-23-9 EFLORNITHINE HYDROCHLORIDE 70050-55-4 ((+)-ISOMER) 69955-42-6 ((-)-ISOMER) PH-3142C 96020-91-6 EFLORNITHINE HYDROCHLORIDE, MONOHYDRATE PH-2131AA 476-66-4 ELLAGIC ACID PH-2131AC 476-66-4 ELLAGIC ACID (REFERENCE GRADE) PH-3676D 518-82-1 EMODIN PH-1062KE 7599-79-3 ENCLOMIPHENE CITRATE PH-5656A 142217-69-4 ENTECAVIR MIS-21419 209783-80-2 ENTINOSTAT MIS-11626 915087-33-1 ENZALUTAMIDE PH-2253AA 56420-45-2 EPIRUBICIN PH-2253AC 56390-09-1 EPIRUBICIN HYDROCHLORIDE PH-1143AA 152044-54-7 EPOTHILONE B PH-1143BA 189453-10-9 EPOTHILONE D PH-1490EA 146665-77-2 EPTAPLATIN PH-1404UA 183321-74-6 ERLOTINIB PH-1404UC 183319-69-9 ERLOTINIB HYDROCHLORIDE PH-1541A 33419-42-0 ETOPOSIDE 35317-32-9 PH-1541C 117091-64-2 ETOPOSIDE PHOSPHATE ® Copyright © 2020 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD.
Load more

Recommended publications
  • Reactivity of Ovariectomised Female Rats After Administration of Injectable Oestrogens by Tem Microscopy
    STUDIA UBB CHEMIA, LXI, 2, 2016 (p. 195-203) (RECOMMENDED CITATION) REACTIVITY OF OVARIECTOMISED FEMALE RATS AFTER ADMINISTRATION OF INJECTABLE OESTROGENS BY TEM MICROSCOPY MOCAN-HOGNOGI RADU FLORINa*, COSTIN NICOLAEa, CONSTANTIN CRACIUNb, MALUTAN ANDREIa, TRIF IOANAa, CIORTEA RAZVANa, MIHU DANa ABSTRACT. The purpose of this electrone microscopy study was to identify and specify structural and ultrastructural changes occurring in the vulvar epithelium of ovariectomised female rats, as well as their reactivity to the administration of injectable oestrogens. We used 30 female Wistar white rats, distributed in four groups with 1 control group, to which oestrogenic treatment was administered. The hormone replacement therapy with injectable oestrogens (Estradiol, Estradurin, Sintofolin), at a dose of 0.2 mg/rat/day was administered for 14 days. Afterwards, all animals were sacrificed and vulvar biopsies were taken, which were then processed using optical microscopy (the semithin section technique) and transmission electron microscopy (TEM) techniques. This study showed that injectable oestrogen treatment over a period of 14 consecutive days enables the recovery of each tissue layer, with regard to the structural and ultrastructural modifications arising in ovariectomised female rats. Keywords: oestrogens, optical microscopy, transmission electron microscopy, structure, atrophy, vulvar hyperplasia INTRODUCTION Variations in estrogen levels strongly affect cell growth and metabolism in a variety of tissues including the vulvo-vaginal epithelium, the ovary and uterus. Estradiol is biosynthesized from progesterone, also produced from cholesterol, via intermediate pregnenolone. One principal pathway then converts progesterone to its 17-hydroxy derivative, 17-hydroxyprogesterone, a Second Clinic of Obstetrics and Gynaecology of the “Iuliu Hatieganu” University of Medicine and Pharmacy 32 Clinicilor Str., RO-400006 * Corresponding author: [email protected] b Center of Electron Microscopy of “Babes-Bolyai” University Str.
    [Show full text]
  • Unlicensed Medicines List for Suffolk D&T
    Unlicensed Medicines & Unlicensed Uses Doctors can prescribe unlicensed medicines, or licensed medicines for unlicensed uses (off-label/off license prescribing). In these situations the doctor is legally responsible for the medicine. They may be called upon to justify their actions in the event of an adverse reaction. Doctors are expected to take “reasonable care” in common law, and to act in a way which is consistent with the practice of a responsible body of their peers of similar professional standing. The General Medical Council guidance on Good Practice in Prescribing Medicines (January 2013) gives the following information for doctors (http://www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp) Prescribing unlicensed medicines You can prescribe unlicensed medicines but, if you decide to do so, you must: 1. Be satisfied that an alternative, licensed medicine would not meet the patient's needs. 2. Be satisfied that there is a sufficient evidence base and/or experience of using the medicine to demonstrate its safety and efficacy. 3. Take responsibility for prescribing the unlicensed medicine and for overseeing the patient's care, including monitoring and any follow up treatment. 4. Record the medicine prescribed and, where you are not following common practice, the reasons for choosing this medicine in the patient's notes. Prescribing medicines for use outside the terms of their licence (off-label) 1. You may prescribe medicines for purposes for which they are not licensed. Although there are a number of circumstances in which this may arise, it is likely to occur most frequently in prescribing for children. Currently pharmaceutical companies do not usually test their medicines on children and as a consequence, cannot apply to license their medicines for use in the treatment of children.
    [Show full text]
  • Treatment of Relapsing Malaria with Specific Antimalarial Drugs In
    Sept., 1947 J TREATMENT OF RELAPSING MALARIA: DESHMUKH 511 up to the expectation. But it soon became Articles clear that they did not control relapse, and Original also that they carry with them a danger of toxicity. Arsenic is notorious for causing to TREATMENT of relapsing malaria damage liver, kidneys and brain. When pregnancy complicates malaria, the use of WITH SPECIFIC ANTIMALARIAL quinine and arsenic may be particularly risky DRUGS IN COMBINATION WITH and one is on the horns of a dilemma as regards PENICILLIN the satisfactory treatment in such circumstances. The writer's experience of arsenicals in By P. L. DESHMUKH, m.d. (Bom.), malaria has been borne out other workers F.C.P.S. by D.T.M.\& II. (Lond.), and their findings in large-scale experiments Poona Sassoon Hospitals, given below will help to dislodge from the minds It must be admitted that even with quinine of the clinicians any lingering faith in arsenic and the synthetic antimalarial drugs like as an ideal antimalarial drug. atabrine, mepacrine, etc. (henceforth called Professor Blacklock (1944) has pointed out specific antimalarials ' for the sake of after long studies at the Liverpool school that tee brevity) treatment of malaria is still very unsatis- though the immediate effects of arsenic in factory. The recognized failure of the specific relapsing malaria were striking, the ultimate antimalarials singly or in combination to control results were disappointing in that practically relapses materially is a matter of great all cases relapsed even after full arsenical concern. A great variation is observed in the treatment. Thus, arsenicals though immediately mterval that may before the occurrence effective against vivax parasites do not eliminate a elapse y relapse.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Light Sensitive Eruptions Treated with Atabrine and Chloroquine John M
    LIGHT SENSITIVE ERUPTIONS TREATED WITH ATABRINE AND CHLOROQUINE JOHN M. KNOX, M.D.,JOHNH. LAMB,Ml)., BEDFORDSHELMIRE, M.D.,AND ROBERT J. MORGAN, M.D. In April 1951 a 50-year-old female, a Red Cross worker recently returned from India, came to one of us (J. M. K.) at Keesler Air Force Base, Biloxi, Mississippi. While in India she had taken atabrine for its antimalarial action. During the period that her skin was yellowed by atabrine pigmentation she had noticed a conspicuous decrease in the severity of a long-standing light-sensitive eruption, prurigo aestivale. The annoying disease was beginning to reappear arid she preferred a return of the yellow discoloration to the eruption. Her response tG atabrine was so noteworthy that later a man 28 years of age with a plaque-like, light-sensitive eruption of the face was given a similar therapeutic trial with the same success. The improvement noted in these two cases, plus the appearance of reports by Page (la) and others (ib, c, d) on atabrine in discoid lupus erythematosus encouraged a clinical evaluation of this drug for the treatment of light-sensitive eruptions. Black (2), in a report of the use of mepacrine in lupus erythematosus, tested four patients with actinic dermatitis with this preparation. No description of the types of dermatitis was recorded. Two female patients were cleared; they had had the disease each summer for 11 and 30 years respectively. The condition of the other two patients (who were males) was unaltered by this drug. DISCUSSION Figure 1 gives a summary of the 18 cases of various types of solar dermatitis.
    [Show full text]
  • UNITED STATES PATENT OFFICE 2,385,853 Processes Foe PRODUCING Hormones Stockton G
    Patented Oct 2, 1945 2,385,853 UNITED STATES PATENT OFFICE 2,385,853 PROCESSEs FoE PRODUCING HoRMoNEs Stockton G. Turnbul, Jr., Wilmington, Del, as sinor to E. I. du Pont de Nemours & Company, Wilmington, Del, a corporation of Delaware NoDrawin. Application August 17, 1943, Serial No. 498,984 2 Claims. (CL 260-619) This invention relates to new and inexpensive 150-watt projector flood lamp, a solution of 9.6 processes for producing hormones and in partica parts of bromine in 50 parts by volume of carbon ular synthetic estrogens, tetrachloride was added dropwise over 3.5 hours It is an object of this invention to produce hors in Such a Way that the heat evolved in the reac mones by means of a new and relatively inexpen tion maintained the reaction mixture at a gentle sive process. A further object is to produce syn reflux, Hydrogen bromide was evolved. The thetic estrogens by a simple and easily controlled pale yellow solution was then cooled and ex process. A still further object is to produce hor tracted twice with 5% sodium sulfite and was mones by a process which avoids many of the dis then dried over sodium sulfate and concentrated advantages of the prior art processes. Addi 10 under vacuum. The 20 parts of oil and crystals . tional objects will become apparent from a con thus obtained was slurried in cold acetone which sideration of the following description and gave 7 parts of white crystals. Upon recrystal claims. lization from ethyl acetate the 3,4-di-Cp-anisyl)r These objects are attained in accordance with 3,4-dibromohexane was obtained as white crys the hereinafter described invention wherein a tals tnat darkened sligntly at 115° C.
    [Show full text]
  • Mepacrine Hydrochloride/Metronidazole
    Mepacrine Hydrochloride/Metronidazole 837 mothorax but the treatment is associated with pain and a high Metronidazole Hydrochloride (BANM, USAN, rINNM) lung cancer, although all 4 were in women who were smokers. frequency of toxic effects. Subsequent follow-up4 to 1984, covering a period of 15 to 25 Hidrocloruro de metronidazol; Métronidazole, Chlorhydrate de; Preparations years, still showed an excess of lung cancer cases even after al- Metronidazoli Hydrochloridum; SC-32642. lowing for smoking status. However, this follow-up also contin- Proprietary Preparations (details are given in Part 3) Метронидазола Гидрохлорид ued to show no significant increase overall in cancer-related India: Maladin. 5 C6H9N3O3,HCl = 207.6. morbidity or mortality. Follow-up of the patients from the sec- CAS — 69198-10-3. ond study for 11 to 15 years to 1984 also showed no increase in ATC — A01AB17; D06BX01; G01AF01; J01XD01; the overall incidence of cancers nor did it confirm any increase Methyl Benzoquate (BAN) P01AB01. in lung cancer. ATC Vet — QA01AB17; QD06BX01; QG01AF01; Risks to the fetus are discussed under Pregnancy in Precautions, Nequinate (USAN, pINN); AY-20385; ICI-55052; Néquinate; Ne- QJ01XD01; QP51AA01. below. quinato; Nequinatum. Methyl 7-benzyloxy-6-butyl-1,4-dihydro- 1. Bendesky A, et al. Is metronidazole carcinogenic? Mutat Res 4-oxoquinoline-3-carboxylate. Incompatibility. Solutions of metronidazole hydrochloride have a low pH, usually of less than 2.0, before dilution and neu- 2002; 511: 133–44. Нехинат 2. Beard CM, et al. Lack of evidence for cancer due to use of met- tralisation for intravenous use. These undiluted solutions react ronidazole. N Engl J Med 1979; 301: 519–22.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Download PDF the Influence of Hexestrol Diacetate on Gametogene
    Rom J Morphol Embryol 2011, 52(1 Suppl):413–417 R J M E RIGINAL APER Romanian Journal of O P Morphology & Embryology http://www.rjme.ro/ The influence of hexestrol diacetate on gametogene function in male rabbit A. R. POP1), I. GROZA1), V. MICLĂUŞ2), SIMONA CIUPE1), GABRIELA MUŢIU3), M. BORZAN1) 1)Department of Reproduction, Gynecology and Obstetrics 2)Department of Histology University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca 3)Department of Histology, Faculty of Medicine and Pharmacy, University of Oradea Abstract The research was performed on 24 male sexually mature domestic rabbits, divided in two equal batches. The rabbits from the first batch were administered 0.5 mg/kg of body weight hexestrol diacetate intramuscularly twice a week for four consecutive weeks. Batch 2 was used for control. The testicular tissue samples obtained after orchidectomy were processed in order to obtain histological samples, stained using the Goldner’s trichrome method. Examination of histological sections from the control batch showed that a natural aspect of seminal tubule epithelium, without reported injuries, even discrete. In the experimental batch were recorded a number of changes to all categories of the seminal cells. The severity and extent of damages varied greatly from one seminal tube to another and even from one part to another of the same seminal tube. These changes were the appearance of apoptotic cells and apoptotic bodies, vacuolar degenerescence of spermatocytes and spermatides, syncitialisation of spermatides, areas of necrosis accompanied by severe disruption of the seminiferous epithelium. In some areas, the lesions were so severe that the affected area of the cells forms “basal area”.
    [Show full text]
  • Sawbones 318: Hydroxychloroquine Published on April 12Th, 2020 Listen on Themcelroy.Family Clint
    Sawbones 318: Hydroxychloroquine Published on April 12th, 2020 Listen on TheMcElroy.family Clint: Sawbones is a show about medical history, and nothing the hosts say should be taken as medical advice or opinion. It‘s for fun. Can't you just have fun for an hour and not try to diagnose your mystery boil? We think you've earned it. Just sit back, relax, and enjoy a moment of distraction from that weird growth. You're worth it [theme music plays] Justin: Hello everybody, and welcome to Sawbones, a marital tour of misguided medicine. I'm your co-host, Justin McElroy. Sydnee: And I'm Sydnee McElroy. Justin: Uh, Syd, y'know, it seems really unfair, in this day and age… lots is unfair about this situation we find ourselves in. The unpleasantness, as I have called it repeatedly. Sydnee: Yes. Justin: It isn't catching on, but that‘s okay. I'm patient. I've got nothing to do but wait. Sydnee: That‘s a bit of an understatement, but… Justin: Yeah, it is. Sydnee: Carry on. Justin: It is. That‘s fair. The very unpleasantness? Super unpleasant? I'll work on it. Um… Sydnee: I don't know. A lot of people are calling it the dystopian—the sickness. Justin: The sickness is like, very… Sydnee: It‘s quite dystopian. Yeah. It‘s hard. Justin: Charlie just says ‗the virus,‘ which is like… accurate. Sydnee: Yes. Justin: But lacks some amount of pageantry. Um, no, it seems unfair, because I feel like I have to educate myself about something new every few days.
    [Show full text]